Most of the risk has been baked out with the fundamentals.
I have done this so many times, including explaining how the fast tracking of CHF to Japan, of the improved targetting of stem cell delivery for CHF will help fast tracking and achieving overwhelming efficacy but you want the same information over and over and over.
Why is that?
Why can't you see that having CHF IP now is to MSB's advantage, especially given this clinical and regulatory setting for both Japan and the US, the biggest markets. Oh and the EU will follow.
Q: Why not step back a bit and stop hitting the panic button?
A: Because blind panic is easier.
Over 3 weeks since the Halt , only 1/2 of Ann, SP heading further South, SI ??????, page-188
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.025(2.51%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 97.0¢ | $1.01 | 96.5¢ | $7.757M | 7.884M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 274918 | 97.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.5¢ | 974 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |